Clinical Trial Update: Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients With Relapse/Refractory Large B Cell Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 trial is evaluating the efficacy of epcoritamab in patients with relapsed or refractory diffuse large B-cell lymphoma, employing a response-adaptive d…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Epcoritamab (epcoritamab)

Snippet

Sponsor: Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | Conditions: Large B Cell Lymphoma | Phase 2 | Status: RECRUITING